Table III.
Characteristics of study subjects positive for HCV RNA genotype 1a, 1b, and 3a.
| Characteristics | 1a (n=8) | 1b (n=6) | 3a (n=6) | P-valuea |
|---|---|---|---|---|
| Age (years) | 49 (35–66) | 36 (30–49) | 47 (39–66) | 0.1071 |
| Hemophilia A/B (%) | 7 (87.5)/1 (12.5) | 5 (83.3)/1 (16.7) | 6 (100)/0 (0) | 0.6009 |
| non-LC/LC (%) | 4 (50.0)/4 (50.0) | 3 (50.0)/3 (50.0) | 1 (16.7)/5 (83.3) | 0.3782 |
| Prior infection with HBVb (−/+) (%) | 3 (37.5)/5 (62.5) | 3 (50.0)/3 (50.0) | 1 (16.6)/5 (83.3) | 0.4719 |
| HCV RNA (log IU/ml) | 6.6 (5.3–7.1) | 6.3 (3.3–7.5) | 5.7 (4.6–6.6) | 0.3127 |
| HIV RNA (−/+) (%) | 7 (87.5)/1 (12.5) | 4 (66.6)/2 (33.3) | 5 (83.3)/1 (16.6) | 0.9346 |
| IL28Bc (major/minor) (%) | 3 (100)/0 (0) | 3 (75.0)/1 (25.0) | 4 (100)/0 (0) | 0.3819 |
| Previous IFN therapy (−/+) (%) | 3 (37.5)/5 (62.5) | 2 (33.3)/4 (66.6) | 3 (50.0)/3 (50.0) | 0.8262 |
LC, liver cirrhosis; HBV, hepatitis B virus; IL28B, interleukin 28 B; IFN, interferon. Median and range presented, unless otherwise indicated.
a
P-value was calculated by statistical analysis between HCV non-LC and LC subjects.
b
Positive for ‘Prior infection with HBV’ indicates positive for any one among HBs antigen, HBs antibody, HBc antibody, and HBe antibody.
c
IL28B indicated IL28B single-nucleotide polymorphisms (rs8099917).